Matches in DBpedia 2014 for { ?s ?p F-15,599 is a very potent and highly selective 5-HT1A receptor full agonist. It displays functional selectivity (also known as "biased agonism") by strongly activating 5-HT1A receptors in the prefrontal cortex while having little effect on autoreceptors in the raphe nucleus. As a result, it has been touted as a preferential postsynaptic 5-HT1A receptor agonist and has been investigated as a novel potential antidepressant.In cognitive tests in rodent, F-15,599 attenuates memory deficits elicited by the NMDA receptor antagonist PCP, suggesting that it may improve cognitive function in disorders such as schizophrenia.A subsequent study showed that F-15,599 reduces breathing irregularity and apneas observed in mice with mutations of the MeCP2 gene. Dysruption of MeCP2 gene expression underlies Rett syndrome, a debilitating neurodevelopmental orphan disease.F-15,599 was discovered and developed by Pierre Fabre Médicament, a French pharmaceuticals company. In September 2013, F-15,599 was out-licensed to Neurolixis Inc, a California-based biotechnology company. Neurolixis announced that it intends to re-purpose F-15,599 for the treatment of Rett syndrome. and obtained Orphan Drug designation from the U.S. Food and Drug Administration (FDA) and from the European Commission for this indication.. }
Showing items 1 to 1 of
1
with 100 items per page.
- F-15,599 abstract "F-15,599 is a very potent and highly selective 5-HT1A receptor full agonist. It displays functional selectivity (also known as "biased agonism") by strongly activating 5-HT1A receptors in the prefrontal cortex while having little effect on autoreceptors in the raphe nucleus. As a result, it has been touted as a preferential postsynaptic 5-HT1A receptor agonist and has been investigated as a novel potential antidepressant.In cognitive tests in rodent, F-15,599 attenuates memory deficits elicited by the NMDA receptor antagonist PCP, suggesting that it may improve cognitive function in disorders such as schizophrenia.A subsequent study showed that F-15,599 reduces breathing irregularity and apneas observed in mice with mutations of the MeCP2 gene. Dysruption of MeCP2 gene expression underlies Rett syndrome, a debilitating neurodevelopmental orphan disease.F-15,599 was discovered and developed by Pierre Fabre Médicament, a French pharmaceuticals company. In September 2013, F-15,599 was out-licensed to Neurolixis Inc, a California-based biotechnology company. Neurolixis announced that it intends to re-purpose F-15,599 for the treatment of Rett syndrome. and obtained Orphan Drug designation from the U.S. Food and Drug Administration (FDA) and from the European Commission for this indication.".